Posted by Michael Wonder on 04 Sep 2021
GSK’s shingles vaccine Shingrix gains UK license
2 September 2021 - GlaxoSmithKline's Shingrix has been licensed in the UK for the prevention of shingles in adults aged 50 years and older, as well as in adults 18 years of age or older who are at increased risk of shingles.
Shingrix (herpes zoster vaccine) is a non-live, recombinant subunit vaccine combining an antigen, glycoprotein E, and an adjuvant system, AS01B. In addition to preventing shingles, the jab also prevents post-herpetic neuralgia, a common complication of shingles.
